353 related articles for article (PubMed ID: 15616299)
21. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients.
Postier RG; Green SL; Klein SR; Ellis-Grosse EJ; Loh E;
Clin Ther; 2004 May; 26(5):704-14. PubMed ID: 15220014
[TBL] [Abstract][Full Text] [Related]
22. In vitro activity of tigecycline against quinolone-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci.
Garrison MW; Nuemiller JJ
Int J Antimicrob Agents; 2007 Feb; 29(2):191-6. PubMed ID: 17174074
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
Bergallo C; Jasovich A; Teglia O; Oliva ME; Lentnek A; de Wouters L; Zlocowski JC; Dukart G; Cooper A; Mallick R;
Diagn Microbiol Infect Dis; 2009 Jan; 63(1):52-61. PubMed ID: 18990531
[TBL] [Abstract][Full Text] [Related]
24. Tigecycline pharmacokinetics in subjects with various degrees of renal function.
Korth-Bradley JM; Troy SM; Matschke K; Muralidharan G; Fruncillo RJ; Speth JL; Raible DG
J Clin Pharmacol; 2012 Sep; 52(9):1379-87. PubMed ID: 21953572
[TBL] [Abstract][Full Text] [Related]
25. Tigecycline penetration into skin and soft tissue.
Stein GE; Smith CL; Missavage A; Saunders JP; Nicolau DP; Battjes SM; Kepros JP
Surg Infect (Larchmt); 2011 Dec; 12(6):465-7. PubMed ID: 22136488
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of a potential tigecycline-warfarin drug interaction.
Zimmerman JJ; Raible DG; Harper DM; Matschke K; Speth JL
Pharmacotherapy; 2008 Jul; 28(7):895-905. PubMed ID: 18576904
[TBL] [Abstract][Full Text] [Related]
27. Tigecycline: a review of a new glycylcycline antibiotic.
Scheinfeld N
J Dermatolog Treat; 2005; 16(4):207-12. PubMed ID: 16249141
[TBL] [Abstract][Full Text] [Related]
28. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials.
Gardiner D; Dukart G; Cooper A; Babinchak T
Clin Infect Dis; 2010 Jan; 50(2):229-38. PubMed ID: 20025527
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and safety of single, multiple, and loading doses of fusidic acid in healthy subjects.
Still JG; Clark K; Degenhardt TP; Scott D; Fernandes P; Gutierrez MJ
Clin Infect Dis; 2011 Jun; 52 Suppl 7():S504-12. PubMed ID: 21546627
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and distribution of minocycline in mature horses after oral administration of multiple doses and comparison with minimum inhibitory concentrations.
Schnabel LV; Papich MG; Divers TJ; Altier C; Aprea MS; McCarrel TM; Fortier LA
Equine Vet J; 2012 Jul; 44(4):453-8. PubMed ID: 21950341
[TBL] [Abstract][Full Text] [Related]
32. Tigecycline: a new glycylcycline antimicrobial.
Townsend ML; Pound MW; Drew RH
Int J Clin Pract; 2006 Dec; 60(12):1662-72. PubMed ID: 17109673
[TBL] [Abstract][Full Text] [Related]
33. Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model.
Koomanachai P; Kim A; Nicolau DP
J Antimicrob Chemother; 2009 May; 63(5):982-7. PubMed ID: 19279050
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects.
Bhavnani SM; Owen JS; Loutit JS; Porter SB; Ambrose PG
Diagn Microbiol Infect Dis; 2004 Oct; 50(2):95-102. PubMed ID: 15474317
[TBL] [Abstract][Full Text] [Related]
35. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.
Abbas R; Hug BA; Leister C; Gaaloul ME; Chalon S; Sonnichsen D
Cancer Chemother Pharmacol; 2012 Jan; 69(1):221-7. PubMed ID: 21691746
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial.
Sacchidanand S; Penn RL; Embil JM; Campos ME; Curcio D; Ellis-Grosse E; Loh E; Rose G
Int J Infect Dis; 2005 Sep; 9(5):251-61. PubMed ID: 16099700
[TBL] [Abstract][Full Text] [Related]
37. Tigecycline: a novel glycylcycline antibiotic.
Zhanel GG; Karlowsky JA; Rubinstein E; Hoban DJ
Expert Rev Anti Infect Ther; 2006 Feb; 4(1):9-25. PubMed ID: 16441206
[TBL] [Abstract][Full Text] [Related]
38. Tigecycline: clinical evidence and formulary positioning.
Nathwani D
Int J Antimicrob Agents; 2005 Mar; 25(3):185-92. PubMed ID: 15737510
[TBL] [Abstract][Full Text] [Related]
39. Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections.
Van Wart SA; Owen JS; Ludwig EA; Meagher AK; Korth-Bradley JM; Cirincione BB
Antimicrob Agents Chemother; 2006 Nov; 50(11):3701-7. PubMed ID: 16940069
[TBL] [Abstract][Full Text] [Related]
40. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
